• 1
    Puthanakit T, Aurpibul L, Oberdorfer P et al. Hospitalization and mortality among HIV-infected children after receiving highly active antiretroviral therapy. Clin Infect Dis 2007; 44: 599604.
  • 2
    Viani RM, Araneta MR, Deville JG, Spector SA. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy. Clin Infect Dis 2004; 39: 725731.
  • 3
    Sanchez JM, Ramos Amador JT, Fernandez de Miguel S et al. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children. Pediatr Infect Dis J 2003; 22: 863867.
  • 4
    Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection, February 23, 2009. US Department of Health and Human Services. Available at 14 April 2009).
  • 5
    Chasombat S, McConnell MS, Siangphoe U et al. National expansion of antiretroviral treatment in Thailand, 2000–2007: program scale-up and patient outcomes. J Acquir Immune Defic Syndr 2009; 50: 506512.
  • 6
    Pillay V, Pillay C, Kantor R, Venter F, Levin L, Morris L. HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. AIDS Res Hum Retroviruses 2008; 24: 14491454.
  • 7
    Kamya MR, Mayanja-Kizza H, Kambugu A et al. Predictors of long-term viral failure among Ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr 2007; 46: 187193.
  • 8
    Sungkanuparph S, Apiwattanakul N, Thitithanyanont A, Chantratita W, Sirinavin S. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Southeast Asian J Trop Med Public Health 2009; 40: 8388.
  • 9
    Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007; 44: 447452.
  • 10
    Jayaweera DT, Espinoza L, Castro J. Etravirine: the renaissance of non-nucleoside reverse transcriptase inhibitors. Expert Opin Pharmacother 2008; 9: 30833094.
  • 11
    Johnson LB, Saravolatz LD. Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor. Clin Infect Dis 2009; 48: 11231128.
  • 12
    Madruga JV, Cahn P, Grinsztejn B et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370: 2938.
  • 13
    Johnson VA, Brun-Vezinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1. Top HIV Med 2008; 16: 138145.
  • 14
    Mascolini M. Monogram devises weighted genotypic score to predict etravirine response. XVII International Drug Resistance Workshop, Spain. June, 2008. Available at
  • 15
    Sirivichayakul S, Ruxrungtham K, Ungsedhapand C et al. Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors. AIDS (London, England) 2003; 17: 18891896.
  • 16
    Sohn AH, Ananworanich J. HAART for children with treatment failure. HIV Therapy 2009; 3: 485499.
  • 17
    Lapphra K, Vanprapar N, Chearskul S et al. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children. Int J Infect Dis 2008; 12: e33e38.
  • 18
    Jittamala P, Puthanakit T, Chaiinseeard S, Sirisanthana V. Predictors of virologic failure and genotypic resistance mutation patterns in Thai children receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Pediatr Infect Dis J 2009; 28: 826830.
  • 19
    Prasitsuebsai W, Bowen A, Pang J, Hesp C, Kariminia A, Sohn AH. Pediatric HIV Clinical Care Resources and Management Practices in Asia: A Regional Survey of the TREAT Asia Pediatric Network. AIDS Patient Care STDS 2010 [Epub ahead of print].
  • 20
    Miller MD, Margot N, Lu B et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis 2004; 189: 837846.
  • 21
    Hosseinipour MC, Van Oosterhout JJ, Weigel R et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS (London, England) 2009; 23: 11271134.
  • 22
    Bannister WP, Ruiz L, Cozzi-Lepri A et al. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. AIDS (London, England) 2008; 22: 367376.
  • 23
    Kekitinwa A, Friedman D, Coakley E, Lie Y, Graziano F. Profiling etravirine resistance in Ugandan children with extended failure of a NNRTI-inclusive regimen as first line ART. Presented at 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, February 8–11, 2009 [Abstract 891].
  • 24
    Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chantratita W. Evaluating the role of etravirine in the second-line antiretroviral therapy after failing an initial non-nucleoside reverse transcriptase inhibitor-based regimen in a resource-limited setting. Curr HIV Res 2008; 6: 474476.
  • 25
    Gupta RK, Hill A, Sawyer AW et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 409417.
  • 26
    Marconi A, Balestrieri M, Comastri G et al. Evaluation of the Abbott Real-Time HIV-1 quantitative assay with dried blood spot specimens. Clin Microbiol Infect 2009; 15: 9397.